Fourth-Line Follicular Lymphoma: CAR-T or a Bispecific, and How Fast the Disease Is Moving
He's already burned through three lines of therapy. The drug class his ulcerative colitis would have ruled out has, as it happens, already been ruled out by the market — leaving a real two-way choice that turns less on efficacy than on how fast his disease is moving.
Bernard K. still plays a regular Thursday night set at the same club he's held a standing gig at for fifteen years, telling anyone who asks that retirement never quite took because nobody told his hands to stop. He is 66, and his relapsed follicular lymphoma now requires a fourth line of therapy after sequential bendamustine-rituximab, R-CHOP, and lenalidomide-rituximab, each controlling his disease for a shrinking stretch of time before relapse. He remains reasonably fit and active, still performing most weeks even through prior treatment, but carries a history of ulcerative colitis that has been in clinical remission for the past four years on maintenance mesalamine.
That colitis history, on its own, hasn't affected his lymphoma care until this specific decision point. Fourth-line options for relapsed follicular lymphoma now come down to CD19-directed CAR-T therapy and bispecific antibodies such as mosunetuzumab. The PI3K inhibitors, which would have appeared on this list a few years ago, no longer hold a US follicular lymphoma indication at all: idelalisib's and duvelisib's follicular indications were withdrawn in 2021 and 2022, umbralisib was pulled from the market entirely in 2022, and Bayer withdrew copanlisib's application in November 2023 after CHRONOS-4 missed its progression-free survival endpoint.
His colitis is the reason that class would have been closed to him even in the years it was available: PI3K-delta inhibition carries a specific, well-documented immune-mediated colitis risk that concentrates in patients with pre-existing inflammatory bowel disease, and idelalisib's own label records fatal or serious diarrhea or colitis in roughly one patient in six. So the class is doubly ruled out here, once by the market and once by him — which leaves a genuine two-way decision between cellular therapy and a bispecific, and leaves the availability question worth stating out loud rather than assumed. Recent imaging shows progressive lymphadenopathy in two nodal regions since his last cycle of lenalidomide-rituximab, disease movement recent enough that how quickly he needs to start whatever comes next is its own live variable, not a settled backdrop to the drug-class decision.
One option his own history already ruled out
I'd pursue CAR-T. It offers a real chance at a durable, potentially treatment-free remission, which matters more with each successive relapse — ZUMA-5 reported complete responses in roughly four out of five patients with relapsed follicular lymphoma, and the remissions have held far better than anything his last three lines produced. And before anyone raises PI3K inhibitors: there is no longer a PI3K inhibitor carrying a US follicular lymphoma indication, so the class isn't a live option regardless. It's worth saying why it would have been closed to him anyway — that class carries a specific, well-documented risk of immune-mediated colitis in patients with underlying inflammatory bowel disease, and he has exactly that history.
I agree completely on ruling out PI3K inhibitors — that's not in dispute.
But I'd lean toward mosunetuzumab instead of CAR-T. Mosunetuzumab's pivotal study (Budde et al., 2022) reported an overall response rate around 80% with complete responses near 60% in patients with two or more prior lines, and cytokine release syndrome that was overwhelmingly low-grade and confined to the step-up cycle. It has a more manageable outpatient toxicity profile, and just as important, it doesn't require apheresis and a manufacturing wait that can run several weeks. He lives ninety minutes from the nearest CAR-T center, and if his disease is moving quickly, that logistics gap matters as much as any efficacy comparison.
We're unanimous on the PI3K question, and that's worth stating plainly rather than leaving implicit — it closes off an option a reader following this case might otherwise wonder about.
On CAR-T versus the bispecific, I don't think this is purely an efficacy debate. It's as much about how fast his disease is actually moving right now. I'd check apheresis slot availability and manufacturing timelines today, regardless of which is ultimately chosen, so we don't lose time either way. Then decide based on his repeat imaging in two weeks — if it shows rapid progression, the bispecific's faster time-to-treatment may matter more than CAR-T's potentially deeper durability; if it's stable, there's time to pursue CAR-T properly.
Agreed unanimously, and recorded so the reasoning is not lost: PI3K inhibitors are out on availability first — no agent in the class holds a current US follicular lymphoma indication — and would have been out on his colitis history in any case. No dissent among the three voices on either ground.
Genuinely unresolved between CAR-T and mosunetuzumab, and explicitly left that way: apheresis slot and manufacturing-timeline logistics were checked immediately regardless of which is chosen, and the final decision was deferred to his repeat imaging in two weeks, which will show whether his disease pace favors the bispecific's faster time-to-treatment or allows time for CAR-T.